167 related articles for article (PubMed ID: 20882050)
1. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.
Wierda WG; Castro JE; Aguillon R; Sampath D; Jalayer A; McMannis J; Prussak CE; Keating M; Kipps TJ
Leukemia; 2010 Nov; 24(11):1893-900. PubMed ID: 20882050
[TBL] [Abstract][Full Text] [Related]
2. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.
Dicker F; Kater AP; Prada CE; Fukuda T; Castro JE; Sun G; Wang JY; Kipps TJ
Blood; 2006 Nov; 108(10):3450-7. PubMed ID: 16741250
[TBL] [Abstract][Full Text] [Related]
3. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.
Chu P; Deforce D; Pedersen IM; Kim Y; Kitada S; Reed JC; Kipps TJ
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3854-9. PubMed ID: 11891278
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis.
Kater AP; Dicker F; Mangiola M; Welsh K; Houghten R; Ostresh J; Nefzi A; Reed JC; Pinilla C; Kipps TJ
Blood; 2005 Sep; 106(5):1742-8. PubMed ID: 15914559
[TBL] [Abstract][Full Text] [Related]
5. CD154 gene therapy for human B-cell malignancies.
Messmer D; Kipps TJ
Ann N Y Acad Sci; 2005 Dec; 1062():51-60. PubMed ID: 16461788
[TBL] [Abstract][Full Text] [Related]
6. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.
Wierda WG; Cantwell MJ; Woods SJ; Rassenti LZ; Prussak CE; Kipps TJ
Blood; 2000 Nov; 96(9):2917-24. PubMed ID: 11049967
[TBL] [Abstract][Full Text] [Related]
7. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.
Castro JE; Melo-Cardenas J; Urquiza M; Barajas-Gamboa JS; Pakbaz RS; Kipps TJ
Cancer Res; 2012 Jun; 72(12):2937-48. PubMed ID: 22505652
[TBL] [Abstract][Full Text] [Related]
8. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells.
Dicker F; Kater AP; Fukuda T; Kipps TJ
Blood; 2005 Apr; 105(8):3193-8. PubMed ID: 15339846
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
Lapalombella R; Andritsos L; Liu Q; May SE; Browning R; Pham LV; Blum KA; Blum W; Ramanunni A; Raymond CA; Smith LL; Lehman A; Mo X; Jarjoura D; Chen CS; Ford R; Rader C; Muthusamy N; Johnson AJ; Byrd JC
Blood; 2010 Apr; 115(13):2619-29. PubMed ID: 19965642
[TBL] [Abstract][Full Text] [Related]
10. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.
Furman RR; Asgary Z; Mascarenhas JO; Liou HC; Schattner EJ
J Immunol; 2000 Feb; 164(4):2200-6. PubMed ID: 10657675
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells.
Laytragoon-Lewin N; Duhony E; Bai XF; Mellstedt H
Eur J Haematol; 1998 Oct; 61(4):266-71. PubMed ID: 9820634
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression.
Melo-Cardenas J; Urquiza M; Kipps TJ; Castro JE
Cancer Gene Ther; 2012 May; 19(5):336-44. PubMed ID: 22402624
[TBL] [Abstract][Full Text] [Related]
13. CD40 ligand in CLL pathogenesis and therapy.
Schattner EJ
Leuk Lymphoma; 2000 May; 37(5-6):461-72. PubMed ID: 11042507
[TBL] [Abstract][Full Text] [Related]
14. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
Kojima K; Duvvuri S; Ruvolo V; Samaniego F; Younes A; Andreeff M
Cancer; 2012 Feb; 118(4):1023-31. PubMed ID: 21761401
[TBL] [Abstract][Full Text] [Related]
15. Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells.
Li LH; Biagi E; Allen C; Shivakumar R; Weiss JM; Feller S; Yvon E; Fratantoni JC; Liu LN
Cancer Gene Ther; 2006 Feb; 13(2):215-24. PubMed ID: 16082377
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia.
Anether G; Marschitz I; Tinhofer I; Greil R
Blood; 2002 Jan; 99(2):722-3. PubMed ID: 11799965
[No Abstract] [Full Text] [Related]
17. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
[TBL] [Abstract][Full Text] [Related]
18. CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes.
Chu P; Wierda WG; Kipps TJ
Blood; 2000 Jun; 95(12):3853-8. PubMed ID: 10845920
[TBL] [Abstract][Full Text] [Related]
19. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
[TBL] [Abstract][Full Text] [Related]
20. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies.
Wang D; Freeman GJ; Levine H; Ritz J; Robertson MJ
Br J Haematol; 1997 May; 97(2):409-17. PubMed ID: 9163608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
